Evidence map›Paper›PMID 35142956›Full record

ArticleCell biology and toxicology2023

Immortalization-upregulated protein promotes pancreatic cancer progression by regulating NPM1/FHL1-mediated cell-cycle-checkpoint protein activity.

Qiankun Luo, Yanfeng Pan, Qiang Fu, Xu Zhang, Shuai Zhou, Pengfei Yu, Huiyuan Tian, Pan Liu, Song Chen, Hongwei Zhang and 1 more

Open access · hybridAbstract read
In one paragraph

Article in Cell biology and toxicology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.7field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Qiankun Luo *Department of Hepatobilliary and Pancreatic Surgery, Zhengzhou University People's Hospital, Henan Provincial People's Hospital, No.7, Weiwu Rd., Jinshui District, Zhengzhou, 450003, Henan, China.ORCID 0000-0002-6423-0847
Yanfeng Pan *Department of Infection Disease, the First Affiliated Hospital of Zhengzhou University, No. 1, Jianshe East Rd. Erqi District, Zhengzhou, 450003, Henan, China.ORCID 0000-0002-2438-4016
Qiang FuDepartment of Hepatobilliary and Pancreatic Surgery, Zhengzhou University People's Hospital, Henan Provincial People's Hospital, No.7, Weiwu Rd., Jinshui District, Zhengzhou, 450003, Henan, China.
Xu ZhangDepartment of Hepatobilliary and Pancreatic Surgery, Zhengzhou University People's Hospital, Henan Provincial People's Hospital, No.7, Weiwu Rd., Jinshui District, Zhengzhou, 450003, Henan, China.
Shuai ZhouTranslational Research Institute, Henan Provincial People's Hospital, Zhengzhou University People's Hospital, Academy of Medical Sciences, Zhengzhou University, Zhengzhou, 450003, Henan, China.
Pengfei YuDepartment of Hepatobilliary and Pancreatic Surgery, Zhengzhou University People's Hospital, Henan Provincial People's Hospital, No.7, Weiwu Rd., Jinshui District, Zhengzhou, 450003, Henan, China.
Huiyuan TianDepartment of Research and Discipline Development, Henan Provincial People's Hospital, Zhengzhou University People's Hospital, No.7, Weiwu Rd., Jinshui District, Zhengzhou, 450003, Henan, China.
Pan LiuDepartment of Hepatobilliary and Pancreatic Surgery, Zhengzhou University People's Hospital, Henan Provincial People's Hospital, No.7, Weiwu Rd., Jinshui District, Zhengzhou, 450003, Henan, China.
Song ChenTranslational Research Institute, Henan Provincial People's Hospital, Zhengzhou University People's Hospital, Academy of Medical Sciences, Zhengzhou University, Zhengzhou, 450003, Henan, China.
Hongwei ZhangDepartment of Hepatobilliary and Pancreatic Surgery, Zhengzhou University People's Hospital, Henan Provincial People's Hospital, No.7, Weiwu Rd., Jinshui District, Zhengzhou, 450003, Henan, China.
Tao QinDepartment of Hepatobilliary and Pancreatic Surgery, Zhengzhou University People's Hospital, Henan Provincial People's Hospital, No.7, Weiwu Rd., Jinshui District, Zhengzhou, 450003, Henan, China. goodfreecn@163.com.ORCID 0000-0001-8791-3555
Zhengzhou University · CNFirst Affiliated Hospital of Zhengzhou University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immortalization-upregulated protein (IMUP) plays a vital role in cell proliferation and tumor progression. However, its role in pancreatic ductal adenocarcinoma (PDAC) remains unclear. Here, we select IMUP as an alternative gene based on GeneChip analysis of clinical PDAC tissues and transcriptome data from The Cancer Genome Atlas. IMUP expression is upregulated in PDAC tumor tissues. Moreover, high IMUP expression correlates with poor prognosis, while IMUP depletion inhibits PDAC cell proliferation and colony formation capacity in vitro, and decreases xenograft tumor growth in vivo. IMUP downregulation leads to cell-cycle arrest in the S phase. IMUP knockdown increases the expression of four-and-a-half LIM domain protein 1 (FHL1), which regulates the phosphorylation of cell division cycle 25A (CDC25A) by cycle checkpoint kinase 1 (CHK1) and promotes cytoplasmic distribution of CDC25A by interaction with 14-3-3ξ. Furthermore, FHL1 knockdown restores the effects induced by IMUP depletion. Liquid chromatography tandem mass spectrometry and immunoprecipitation analysis further show that IMUP interacts directly with nucleophosmin (NPM1) and enhances its stability. DNA methylation sequencing shows that FHL1 promoter methylation decreases when IMUP is downregulated. Overexpression of NPM1 can increase the methylation level of FHL1, thereby decreasing its expression. Our study provides a novel perspective on IMUP/NPM1/FHL1-mediated cell-cycle arrest by regulating CDC25A phosphorylation in PDAC. These findings may provide a new therapeutic target for PDAC.

Indexed as

Carcinoma, Pancreatic DuctalPancreatic NeoplasmsCell Cycle CheckpointsCell Line, TumorCell ProliferationGene Expression Regulation, NeoplasticHumansIntracellular Signaling Peptides and ProteinsLIM Domain ProteinsMuscle ProteinsNuclear ProteinsNucleophosminTranscription FactorsC19orf33 protein, humanFHL1 protein, humanIntracellular Signaling Peptides and ProteinsLIM Domain ProteinsMuscle ProteinsNPM1 protein, humanNuclear ProteinsNucleophosminTranscription FactorsCell cycleIMUPPancreatic cancerS phase

Identifiers

PMID35142956
PMCPMC10547647
OpenAlexW4225486501

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.